Shenzhen New Industries Biomedical Engineering Co., Ltd. principally engages in the research, development, production, and sale of automatic chemiluminescence immunoassay instruments and supporting reagents. The company was founded on December 15, 1995 and is headquartered in Shenzhen, China.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Manufactures pharmaceuticals

Dongguan Pengzhi Biotechnology Co., Ltd., established on 2016-08-22, Business scope includes biological products,R&D of medical devices,Production,Sales and technology transfer,Technical Services;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.

FAPON is a biotechnology company that provides IVD reagent raw material manufacturing and a one-stop solution. The company provides excellent-performance IVD reagent core raw materials, reagent solutions, and open solutions to global in vitro diagnostic companies. In the field of high-performance in vitro diagnostic reagents, various bioengineering technologies are used, as well as precise screening and the provision of active raw materials.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis, and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time-efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market. Its products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading. ENB Therapeutics was founded in 2015 and is headquartered in New York, New York.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

AdnaGen AG is a biotechnology company that develops molecular genetic diagnostic testing systems for the medical and clinical research laboratories. The company offers AdnaTest kits including reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics. In addition, it focuses on genetic pre-disposition, pharmoco genetics, and non-invasive prenatal diagnostic systems for early detection, prevention, and monitoring of human diseases. The company was founded in 1999 and is headquartered in Langenhagen, Germany. As of February 23, 2006, AdnaGen AG is a subsidiary of OncoVista, Inc.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Ningbo Ruiyuan Biotechnology Co., Ltd. engages in the research, production, and sale of in vitro diagnostic products and the provision of related after-sales services. It produces medical devices and liquid biochemical reagents; as well as provides special packaging for domestic and foreign biochemical analyzers. The company was founded in February 2003 and is headquartered in Ningbo, China.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on five products. UCERIS® (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID® (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.

Jiangsu Yiluo Weisheng Biotechnology Co., Ltd., established on 2013-12-12, Business scope includes biotechnology development,technology transfer,Technical Services;Three categories6840Production of in vitro diagnostic reagents,Sales;one,two,Wholesale of Class III Medical Devices and Diagnostic Reagents;Computer hardware and software,Computer system integration development;cosmetic,daily necessities,Chemical products and raw materials,Instrumentation,rubber products,FRP products sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:software development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Manufactures pharmaceuticals for cardiovascular treatment, central nervous system, internal medicine drugs and oncology treatment

Jiangsu Dajun Biotechnology Co., Ltd., established on 2014-06-04, Business scope includes biotechnology,Technology development of medical devices,technical consulting,Technical Services,technology transfer;Manufacturing and sales of medical devices;biochemical enzyme,antigen,Sales of antibodies and other chemical products(Free of hazardous chemicals and drugs);Food Safety Testing Biological Reagents(Free of Hazardous Chemicals)and instruments(Without measuring instruments)technology development,production and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)